

LAW OFFICES
KILYK & BOWERSOX, P.L.L.C.

RECEIVED
CENTRAL FAX CENTER

NOV 02 2005

Intellectual Property Law

LUKE A. KILYK* (PA, DC)
LEONARD D. BOWERSOX
JASBIR SINGH
MATTHEW T. GILL
RALPH T. WEBB* (DC, TX, LA)

Of Counsel:
LAWRENCE B. BUGAISKY, Ph.D.* (DC)
WILLIAM CHARLES JAMISON, Ph.D.

400 Holiday Court, Suite 102
WARRENTON, VA 20186

TEL.: (540) 428-1701
FAC.: (540) 428-1720
(540) 428-1721

FAIRFAX OFFICE
3603-E Chain Bridge Road
Fairfax, Virginia 22030

Email: lkilyk@kbpatentlaw.com
Website: <http://www.kbpatentlaw.com>

*Admitted only in states indicated

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE: November 2, 2005

TO: Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/537,001
Entitled: COLON CANCER METASTASIS INHIBITOR
Our Ref: 3190-078

FROM: Luke A. Kilyk, Esq. *JK*

FAC. TEL. NO.: 1-571-273-8300

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 11

Items Attached: Supplemental Information Disclosure Statement -- 2 pages
Form PTO SB-08 -- 1 page
Documents -- 7 pages

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on November 2, 2005.

Kim Blum
Name (Print)

Kim Blum
Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

RECEIVED
CENTRAL FAX CENTER

NOV 02 2005

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on November 2, 2005.

Kim Blum
Name (Print)

Kim Blum
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | | |
|-----------------------|----------------|---|-------------------|------------|
| In re Application of: | Akiyama et al. |) | Examiner: | Unassigned |
| | |) | | |
| Application No.: | 10/537,001 |) | Group Art Unit: | Unassigned |
| | |) | | |
| Filed: | May 20, 2005 |) | Confirmation No.: | Unassigned |
| | |) | | |
| Docket No.: | 3190-078 |) | Customer No.: | 33432 |

For: COLON CANCER METASTASIS INHIBITOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 2, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application but before any Office Action on the merits and before any Final Office Action or Notice of Allowance.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. *See* 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application,

Supplemental Information Disclosure Statement
U.S. Patent Application No. 10/537,001


and that the documents cited in the attached Form PTO-SB-08 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-078
KILYK & BOWERSOX, P.L.L.C.
400 Holiday Court, Suite 102
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO-SB-08, w/1 Document

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
OMB Control Number: 0651-0031
Expires through 04/06/2003, OMB 0651-0031

PTO/SB/08a (05-2013)

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a Federal
agency logo or official seal.

| | | | | | | | | | | | | | | | | | |
|---|----------------|----|---|---|--|--------------------|------------|-------------|--------------|----------------------|----------------|----------|------------|---------------|------------|------------------------|----------|
| <p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i></p> | | | | <p>Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>10/537,001</td> </tr> <tr> <td>Filing Date</td> <td>May 20, 2005</td> </tr> <tr> <td>First Named Inventor</td> <td>AKIYAMA et al.</td> </tr> <tr> <td>Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>3190-078</td> </tr> </table> | | Application Number | 10/537,001 | Filing Date | May 20, 2005 | First Named Inventor | AKIYAMA et al. | Art Unit | Unassigned | Examiner Name | Unassigned | Attorney Docket Number | 3190-078 |
| Application Number | 10/537,001 | | | | | | | | | | | | | | | | |
| Filing Date | May 20, 2005 | | | | | | | | | | | | | | | | |
| First Named Inventor | AKIYAMA et al. | | | | | | | | | | | | | | | | |
| Art Unit | Unassigned | | | | | | | | | | | | | | | | |
| Examiner Name | Unassigned | | | | | | | | | | | | | | | | |
| Attorney Docket Number | 3190-078 | | | | | | | | | | | | | | | | |
| Sheet | 1 | of | 1 | | | | | | | | | | | | | | |

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.